Med Sci (Paris)
Volume 34, October 2018Cancer biomarkers
|Page(s)||8 - 14|
|Published online||07 November 2018|
JTC-801 Suppresses Melanoma Cells Growth through the PI3K‑Akt‑mTOR Signaling Pathways
School of Medicine, Shandong University, Jinan, Shandong, P.R. China
2 Department of Dermatology, Shandong Provincial Third Hospital, Jinan, Shandong, P.R. China
3 Department of Dermatology, Yucheng People’s Hospital, No.753, Kaituo Road, Yu Town, Yucheng 251200, Shandong, P.R. China
* Corresponding author: Fei Huang email@example.com
Melanoma is considered as one of the most potentially fatal and aggressive malignancies. Due to the limited efficacy or drug resistance of the current targeted therapies of melanoma, developing new therapeutic drugs against new targets to effectively control tumor growth is greatly needed. In this study, the effect of JTC-801, a selective small-molecule antagonist of nociceptin receptor and analgesic agent, on a melanoma cell line, M14, has been studied. We demonstrate herein that JTC-801 could efficiently suppress the proliferation, migration and invasion capacity of the M14 melanoma cells, and induced a strong apoptosis. Importantly, our results provide the underlying molecular mechanism of these effects. JTC-801 cells regulate M14 cells by inhibiting the PI3K-Akt‑mTOR pathway. These results suggest that JTC-801 should be further studied in preclinical modes to establish whether it represents a potential small anticancer candidate drug against melanoma.
Key words: JTC-801 / melanoma / PI3K / signaling pathway
© 2018 médecine/sciences – Inserm
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.